Table 1.
Characteristics of AECOPD patients according to in-hospital mortality
| Characteristic | Non-survivors (n = 23) | Survivors (n = 296) | P value |
|---|---|---|---|
| Age, years | 80.78 ± 6.58 | 75.09 ± 9.73 | 0.001 |
| BMI, kg/m2 | 20.07 ± 3.97 | 21.05 ± 3.89 | 0.244 |
| Sex, n (%) | 0.308 | ||
| Male | 17 (73.9) | 244 (82.4) | |
| Female | 6 (26.1) | 52 (17.6) | |
| Smoking status, n (%) | 0.920 | ||
| Never smoker | 4 (17.4) | 61 (20.6) | |
| Current/ever smoker | 19 (82.6) | 235 (79.4) | |
| Hospital stay, days | 7.7 ± 4.6 | 8.0 ± 3.0 | 0.795 |
| Exacerbations during preceding year, n (%) | 15 (65.2) | 127 (42.9) | 0.038 |
| GOLD stage, n (%) | 0.771 | ||
| I | 1 (4.3) | 20 (6.7) | |
| II | 11 (47.8) | 110 (37.2) | |
| III | 8 (34.8) | 116 (39.2) | |
| IV | 3 (13.0) | 50 (16.9) | |
| CHF, n (%) | 16 (69.6) | 81 (27.4) | < 0.001 |
| RD, n (%) | 10 (43.5) | 141 (47.6) | 0.701 |
| Bronchiectasis, n (%) | 4 (17.4) | 91 (30.7) | 0.238 |
| Diabetes, n (%) | 2 (8.7) | 30 (10.1) | 0.825 |
| Hypertension, n (%) | 13 (56.5) | 163 (55.1) | 0.893 |
| CHD, n (%) | 8 (34.8) | 76 (25.7) | 0.339 |
| Neutrophil count, × 109/L | 10.27 (7.21–14.04) | 6.58 (4.58–9.04) | < 0.001 |
| Lymphocyte count, × 109/L | 0.85 (0.58–1.21) | 1.22 (0.86–1.72) | 0.001 |
| PH | 7.36 ± 0.15 | 7.40 ± 0.04 | 0.262 |
| PaO2, mmHg | 85.1 ± 33.2 | 90.0 ± 25.2 | 0.382 |
| PaCO2, mmHg | 50.7 ± 23.4 | 44.7 ± 10.2 | 0.231 |
| BUN, mmol/L | 10.86 (7.10–12.25) | 5.35 (4.14–7.40) | < 0.001 |
| ALB, g/L | 32.58 ± 3.72 | 36.26 ± 4.53 | < 0.001 |
| BUN/ALB ratio | 0.329 (0.250–0.399) | 0.145 (0.111–0.210) | < 0.001 |
Variables are expressed as mean ± standard deviation (SD), medians (interquartile range, IQR) or percentages
GOLD Global Initiative for Chronic Obstructive Lung Disease, CHF congestive heart failure, RD renal dysfunction, CHD coronary heart disease, PaO2 arterial oxygen tension, PaCO2 arterial carbon dioxide tension, BUN blood urea nitrogen, ALB albumin, BUN/ALB ratio blood urea nitrogen to serum albumin ratio